Amarin (AMRN) Vascepa Growth Continues; Sees Limited Negative Read-Through from Merck's HPS2-THRIVE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amarin's (AMRN) Vascepa Tracking Well 3-Months In; Investors Eye Tier 2 Designation
April 1, 2013 11:47 AM EDTAmarin (Nasdaq: AMRN) is trading strong amid positive comments from Leerink Swann today.
Analyst Joseph Schwartz said IMS Health's weekly publication of Vascepa prescription data are tracking well. The largest TRx advance since launch was recorded last week, with 1,504 recorded last week, while refills and new prescriptions are picking up.
Vascepa is tracking in-line with other... More
Amarin (AMRN) Receives Additional Patent Allowance for Vascepa
March 7, 2013 8:00 AM ESTAmarin Corporation plc (Nasdaq: AMRN) announced that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable Pharmaceutical Compositions and Methods of Using the Same." This application includes claims intended to protect the proposed Vascepa® (icosapent ethyl) indication based on Amarin's Phase 3 ANCHOR clinical trial results. In late... More
